Published in AIDS Weekly, June 10th, 1996
PMEA [9-(2-phosphonylmethoxyethyl)-adenine] is the prototypic compound for a new class of drugs active against HIV, herpesviruses, and hepatitis viruses. Unlike nucleoside analogs (AZT, ddI, ddC, d4T, etc.), these nucleotide analogs are already in their active form and do not require intracellular processing for activation.
An orally bioavailable form of PMEA, bis-POM-PMEA or adefovir dipivoxil, is being tested for anti-HIV and anti-hepatitis B efficacy in clinical trials.
Now researchers at the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.